miRNAs Related to Immune Checkpoint Inhibitor Response: A Systematic Review.

Fecha de publicación: 01/02/2024 Fecha Ahead of Print: 01/02/2024

Autores de IIS La Fe

Agustín Lahoz Rodríguez

Autor

Participantes ajenos a IIS La Fe

García-Giménez JL
Saadi W
Ortega AL
Suay G
Carretero J
Pereda J
Fatmi A
Pallardó FV
Mena-Molla S

Grupos

Unidad de Biomarcadores y Medicina de Precisión (UBYMP)

Leader

Agustín Lahoz Rodríguez

Abstract

The advent of immune checkpoint inhibitors (ICIs) has represented a breakthrough in the treatment of many cancers, although a high number of patients fail to respond to ICIs, which is partially due to the ability of tumor cells to evade immune system surveillance. Non-coding microRNAs (miRNAs) have been shown to modulate the immune evasion of tumor cells, and there is thus growing interest in elucidating whether these miRNAs could be targetable or proposed as novel biomarkers for prognosis and treatment response to ICIs. We therefore performed an extensive literature analysis to evaluate the clinical utility of miRNAs with a confirmed direct relationship with treatment response to ICIs. As a result of this systematic review, we have stratified the miRNA landscape into (i) miRNAs whose levels directly modulate response to ICIs, (ii) miRNAs whose expression is modulated by ICIs, and (iii) miRNAs that directly elicit toxic effects or participate in immune-related adverse events (irAEs) caused by ICIs.

Datos de la publicación

ISSN/ISSNe:: 1661-6596, 1661-6596
Tipo:: Article
Páginas:: -
DOI:: 10.3390/ijms25031737
Factor de Impacto:: 1,176 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

García-Giménez JL:: Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain

INCLIVA Health Research Institute, INCLIVA, 46010 Valencia, Spain

Consortium Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, 46010 Valencia, Spain
Saadi W:: Department of Biology, Faculty of Nature, Life and Earth Sciences, University of Djillali Bounaama, Khemis Miliana 44225, Algeria
Ortega AL:: Department of Physiology, Faculty of Pharmacy, University of Valencia, 46100 Burjassot, Spain
Lahoz A:: Biomarkers and Precision Medicine Unit, Health Research Institute-Hospital La Fe, 46026 Valencia, Spain

Analytical Unit, Health Research Institute-Hospital La Fe, 46026 Valencia, Spain
Suay G:: Medical Oncology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
Carretero J:: Department of Physiology, Faculty of Pharmacy, University of Valencia, 46100 Burjassot, Spain
Pereda J:: Department of Physiology, Faculty of Pharmacy, University of Valencia, 46100 Burjassot, Spain
Fatmi A:: Department of Microbiology & Biochemistry, Faculty of Science, University of M'sila, M'sila 28000, Algeria
Pallardó FV:: Department of Physiology, Faculty of Medicine and Dentistry, University of Valencia, 46010 Valencia, Spain

INCLIVA Health Research Institute, INCLIVA, 46010 Valencia, Spain

Consortium Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, 46010 Valencia, Spain
Mena-Molla S:: INCLIVA Health Research Institute, INCLIVA, 46010 Valencia, Spain

Department of Physiology, Faculty of Pharmacy, University of Valencia, 46100 Burjassot, Spain